Clinical Trial Update: A Biomarker Study of Solanezumab in Patients With and Without Alzheimer's [Phase 2]

View source ↗

Summary

A Phase 2 biomarker study evaluating solanezumab in patients with and without Alzheimer's disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Solanezumab (solanezumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Alzheimer's Disease | Phase 2 | Status: COMPLETED